DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Sulkowski M, Hezode C, Gerstoft J. et al.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet 2015;
385 (9973): 1087-1097
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.